KIF4A and epilepsy: Therefore, while PARP1 plays a neuroprotective role under normal conditions, its reduced activity due to KIF4 mutation becomes a risk factor for epilepsy, highlighting PARP1 as a potential therapeutic target for antiepileptic interventions.